| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net revenue | $3.24B-0.5% | $3.26B+1.9% | $3.20B+7.7% | $2.97B+21.0% | $2.45B+132.4% | $1.06B+99.5% | $529.6M |
| Cost of net revenue | $2.64B+2.2% | $2.58B+0.1% | $2.58B+7.8% | $2.39B+19.0% | $2.01B+123.6% | $898.6M+103.9% | $440.7M |
| General and administrative expenses | $382.3M+6.4% | $359.2M+7.4% | $334.6M+3.0% | $324.8M+93.9% | $167.5M+87.5% | $89.3M+58.2% | $56.5M |
| Depreciation and amortization, excluding patient equipment depreciation | $40.6M-9.8% | $45.0M-21.1% | $57.1M-12.0% | $64.9M+2.8% | $63.1M+454.8% | $11.4M+270.7% | $3.1M |
| Goodwill impairment (note 7) | $128.0M+878.7% | $13.1M-98.4% | $830.8M | $0 | $0 | — | — |
| Total costs and expenses | $3.19B+6.3% | $3.00B-21.1% | $3.80B+36.6% | $2.78B+24.1% | $2.24B+124.1% | $999.3M+99.8% | $500.3M |
| Gain on sale of businesses (note 4) | -$32.6M | $0 | $0 | — | — | — | — |
| Operating income (loss) | $90.9M-65.5% | $263.7M+144.1% | -$598.4M-414.3% | $190.4M-15.6% | $225.6M+216.2% | $71.3M+142.9% | $29.4M |
| Interest expense, net | $105.8M-16.5% | $126.7M-2.8% | $130.3M+19.1% | $109.4M+14.9% | $95.2M+129.8% | $41.4M+5.4% | $39.3M |
| Loss on extinguishment of debt | $0-100.0% | $2.3M | $0 | $0-100.0% | $20.2M+279.8% | $5.3M+150.6% | $2.1M |
| Change in fair value of warrant liability (note 13) | $0+100.0% | -$4.0M+88.3% | -$34.5M-101.0% | -$17.2M+67.7% | -$53.2M-139.3% | $135.4M+1669.5% | $7.7M |
| Other loss, net | $274K-90.2% | $2.8M-90.6% | $29.6M+11586.2% | $253K-86.2% | $1.8M+153.2% | -$3.4M-983.0% | -$318K |
| (Loss) income before income taxes | -$15.2M-111.1% | $136.0M+118.8% | -$723.8M-839.3% | $97.9M-48.7% | $191.0M+192.7% | -$206.0M-842.5% | -$21.9M |
| Income tax expense (benefit) | $50.9M+23.4% | $41.2M+184.2% | -$49.0M-297.8% | $24.8M-24.5% | $32.8M+374.4% | -$12.0M-1717.7% | $739K |
| Net (loss) income | -$66.0M-169.7% | $94.8M+114.0% | -$674.8M-1022.7% | $73.1M-53.8% | $158.2M+181.5% | -$194.1M-758.7% | -$22.6M |
| Income attributable to noncontrolling interest | $4.8M+9.1% | $4.4M+5.9% | $4.1M+7.8% | $3.8M+93.0% | $2.0M+106.1% | -$32.5M-2475.7% | -$1.3M |
| Net (loss) income attributable to AdaptHealth Corp. | -$70.8M-178.3% | $90.4M+113.3% | -$678.9M-1079.4% | $69.3M-55.6% | $156.2M+196.6% | -$161.6M-657.4% | -$21.3M |
| Weighted average common shares outstanding - basic (in shares) | 135.1M+1.0% | 133.8M-0.3% | 134.2M-0.0% | 134.2M+6.2% | 126.3M+140.6% | 52.5M+132.7% | 22.6M |
| Weighted average common shares outstanding - diluted (in shares) | 135.1M-0.3% | 135.5M+0.8% | 134.4M-3.3% | 139.0M+4.5% | 133.0M+153.5% | 52.5M+132.7% | 22.6M |
| Basic net (loss) income per share (in dollars per share) | -$520.00-183.9% | $620.00+112.3% | -$5060.00-1176.6% | $470.00-58.0% | $1120.00+136.4% | -$3080.00 | — |
| Diluted net (loss) income per share (in dollars per share) | -$520.00-185.2% | $610.00+111.5% | -$5310.00-1709.1% | $330.00-50.7% | $670.00+121.8% | -$3080.00-224.2% | -$950.00 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.